# Coherus Oncology, Inc.: financial statements, quarterly

CHRS · Nasdaq · CIK 1512762 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/chrs.md) · [Financials](/companies/chrs/financials.md) · [Filings](/companies/chrs/filings.md) · [Insiders](/companies/chrs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/chrs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [74.6](/filings/0001558370-24-014648.md) | [91.5 d](/filings/0001558370-25-003126.md) | [2.3](/filings/0001558370-25-007418.md) | [10.3](/filings/0001558370-25-010803.md) | [6.1](/filings/0001104659-25-107852.md) | [7.7 d](/filings/0001104659-26-025308.md) | [7.6](/filings/0001104659-26-058703.md) | [10.3](/filings/0001104659-26-091262.md) | [11.6](/filings/0001104659-25-107852.md) | [12.7 d](/filings/0001104659-26-025308.md) | [12.3](/filings/0001104659-26-058703.md) | [14.3](/filings/0001104659-26-091262.md) |
| Cost of revenue | $m | [32.7](/filings/0001558370-24-014648.md) | [84.6 d](/filings/0001558370-25-003126.md) | [1.4](/filings/0001558370-25-007418.md) | [1.8](/filings/0001558370-25-010803.md) | [2.7](/filings/0001104659-25-107852.md) | [2.8 d](/filings/0001104659-26-025308.md) | [2.7](/filings/0001104659-26-058703.md) | [3.4](/filings/0001104659-26-091262.md) | [3.7](/filings/0001104659-25-107852.md) | [4.0 d](/filings/0001104659-26-025308.md) | [3.8](/filings/0001104659-26-058703.md) | [4.2](/filings/0001104659-26-091262.md) |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [25.6](/filings/0001558370-24-014648.md) | [26.4 d](/filings/0001558370-25-003126.md) | [28.4](/filings/0001558370-25-007418.md) | [20.6](/filings/0001558370-25-010803.md) | [22.1](/filings/0001104659-25-107852.md) | [20.8 d](/filings/0001104659-26-025308.md) | [24.4](/filings/0001104659-26-058703.md) | [26.3](/filings/0001104659-26-091262.md) | [27.3](/filings/0001104659-25-107852.md) | [31.0 d](/filings/0001104659-26-025308.md) | [21.5](/filings/0001104659-26-058703.md) | [21.4](/filings/0001104659-26-091262.md) |
| Selling, general and administrative | $m | [48.2](/filings/0001558370-24-014648.md) | [49.5 d](/filings/0001558370-25-003126.md) | [40.2](/filings/0001558370-25-007418.md) | [27.5](/filings/0001558370-25-010803.md) | [28.1](/filings/0001104659-25-107852.md) | [29.6 d](/filings/0001104659-26-025308.md) | [26.0](/filings/0001104659-26-058703.md) | [26.0](/filings/0001104659-26-091262.md) | [24.9](/filings/0001104659-25-107852.md) | [23.6 d](/filings/0001104659-26-025308.md) | [23.1](/filings/0001104659-26-058703.md) | [21.0](/filings/0001104659-26-091262.md) |
| Operating income | $m | [(32.0)](/filings/0001558370-24-014648.md) | [(68.9) d](/filings/0001558370-25-003126.md) | [(67.8)](/filings/0001558370-25-007418.md) | [(39.6)](/filings/0001558370-25-010803.md) | [(46.9)](/filings/0001104659-25-107852.md) | [(45.4) d](/filings/0001104659-26-025308.md) | [(45.4)](/filings/0001104659-26-058703.md) | [(45.5)](/filings/0001104659-26-091262.md) | [(44.3)](/filings/0001104659-25-107852.md) | [(45.9) d](/filings/0001104659-26-025308.md) | [(36.2)](/filings/0001104659-26-058703.md) | [(32.3)](/filings/0001104659-26-091262.md) |
| Interest expense | $m | [10.3](/filings/0001558370-24-014648.md) | [10.6 d](/filings/0001558370-25-003126.md) | [3.1](/filings/0001558370-25-007418.md) | [4.1](/filings/0001558370-25-010803.md) | [2.8](/filings/0001104659-25-107852.md) | [1.9 d](/filings/0001104659-26-025308.md) | [2.2](/filings/0001104659-26-058703.md) | [2.3](/filings/0001104659-26-091262.md) | [2.3](/filings/0001104659-25-107852.md) | [2.2 d](/filings/0001104659-26-025308.md) | [2.2](/filings/0001104659-26-058703.md) | [2.3](/filings/0001104659-26-091262.md) |
| Income tax | $m | [(0.4)](/filings/0001558370-24-014648.md) | [0.0 d](/filings/0001558370-25-003126.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(39.6)](/filings/0001558370-24-014648.md) | [(79.7) d](/filings/0001558370-25-003126.md) | [103](/filings/0001104659-25-107852.md) | [(12.9)](/filings/0001104659-25-107852.md) | [(10.8)](/filings/0001104659-25-107852.md) | [(50.7) d](/filings/0001104659-26-025308.md) | [(56.6)](/filings/0001104659-26-091262.md) | [298](/filings/0001104659-26-091262.md) | [(35.5)](/filings/0001104659-25-107852.md) | [(37.6) d](/filings/0001104659-26-025308.md) | [(38.3)](/filings/0001104659-26-091262.md) | [(20.6)](/filings/0001104659-26-091262.md) |
| Diluted EPS | $ per share | [(0.41)](/filings/0001558370-24-014648.md) | not reported | [0.91](/filings/0001558370-25-007418.md) | [(0.11)](/filings/0001558370-25-010803.md) | [(0.09)](/filings/0001104659-25-107852.md) | not reported | [2.57](/filings/0001104659-26-091262.md) | [2.57](/filings/0001104659-26-091262.md) | [(0.31)](/filings/0001104659-25-107852.md) | not reported | [(0.28)](/filings/0001104659-26-058703.md) | [(0.13)](/filings/0001104659-26-091262.md) |
| Basic EPS | $ per share | [(0.41)](/filings/0001558370-24-014648.md) | not reported | [0.91](/filings/0001558370-25-007418.md) | [(0.11)](/filings/0001558370-25-010803.md) | [(0.09)](/filings/0001104659-25-107852.md) | not reported | [(0.49)](/filings/0001104659-26-058703.md) | [2.57](/filings/0001104659-26-091262.md) | [(0.31)](/filings/0001104659-25-107852.md) | not reported | [(0.28)](/filings/0001104659-26-058703.md) | [(0.13)](/filings/0001104659-26-091262.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [80.3](/filings/0001558370-24-014648.md) | [103](/filings/0001558370-25-003126.md) | [260](/filings/0001558370-24-007641.md) | [159](/filings/0001558370-24-011629.md) | [97.7](/filings/0001558370-24-014648.md) | [126](/filings/0001104659-26-025308.md) | [82.4](/filings/0001558370-25-007418.md) | [217](/filings/0001558370-25-010803.md) | [103](/filings/0001104659-25-107852.md) | [88.9](/filings/0001104659-26-091262.md) | [115](/filings/0001104659-26-058703.md) | [82.9](/filings/0001104659-26-091262.md) |
| Current assets | $m | [444](/filings/0001558370-23-017779.md) | [476](/filings/0001558370-25-003126.md) | [627](/filings/0001558370-24-007641.md) | [558](/filings/0001558370-24-011629.md) | [369](/filings/0001558370-24-014648.md) | [342](/filings/0001104659-26-025308.md) | [310](/filings/0001558370-25-007418.md) | [380](/filings/0001558370-25-010803.md) | [461](/filings/0001104659-25-107852.md) | [207](/filings/0001104659-26-091262.md) | [206](/filings/0001104659-26-058703.md) | [134](/filings/0001104659-26-091262.md) |
| Total assets | $m | [584](/filings/0001558370-23-017779.md) | [630](/filings/0001558370-25-003126.md) | [764](/filings/0001558370-24-007641.md) | [675](/filings/0001558370-24-011629.md) | [505](/filings/0001558370-24-014648.md) | [449](/filings/0001104659-26-025308.md) | [371](/filings/0001558370-25-007418.md) | [439](/filings/0001558370-25-010803.md) | [517](/filings/0001104659-25-107852.md) | [258](/filings/0001104659-26-091262.md) | [266](/filings/0001104659-26-058703.md) | [191](/filings/0001104659-26-091262.md) |
| Current liabilities | $m | [240](/filings/0001558370-23-017779.md) | [332](/filings/0001558370-25-003126.md) | [538](/filings/0001558370-24-007641.md) | [463](/filings/0001558370-24-011629.md) | [296](/filings/0001558370-24-014648.md) | [283](/filings/0001104659-26-025308.md) | [255](/filings/0001558370-25-007418.md) | [264](/filings/0001558370-25-010803.md) | [372](/filings/0001104659-25-107852.md) | [140](/filings/0001104659-26-091262.md) | [132](/filings/0001104659-26-058703.md) | [75.5](/filings/0001104659-26-091262.md) |
| Total liabilities | $m | [717](/filings/0001558370-23-017779.md) | [823](/filings/0001558370-25-003126.md) | [845](/filings/0001558370-24-007641.md) | [759](/filings/0001558370-24-011629.md) | [593](/filings/0001558370-24-014648.md) | [581](/filings/0001104659-26-025308.md) | [555](/filings/0001558370-25-007418.md) | [320](/filings/0001558370-25-010803.md) | [429](/filings/0001104659-25-107852.md) | [197](/filings/0001104659-26-091262.md) | [187](/filings/0001104659-26-058703.md) | [130](/filings/0001104659-26-091262.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(134)](/filings/0001558370-24-014648.md) | [(193)](/filings/0001104659-26-025308.md) | [(81.8)](/filings/0001104659-25-107852.md) | [(84.1)](/filings/0001104659-25-107852.md) | [(88.0)](/filings/0001104659-25-107852.md) | [(132)](/filings/0001104659-26-091262.md) | [(183)](/filings/0001104659-26-091262.md) | [120](/filings/0001104659-26-091262.md) | [87.8](/filings/0001104659-25-107852.md) | [61.0](/filings/0001104659-26-091262.md) | [78.6](/filings/0001104659-26-091262.md) | [60.8](/filings/0001104659-26-091262.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(54.3) d](/filings/0001558370-24-014648.md) | [(12.9) d](/filings/0001558370-25-003126.md) | [(46.8)](/filings/0001558370-25-007418.md) | [59.7 d](/filings/0001558370-25-010803.md) | [(62.0) d](/filings/0001104659-25-107852.md) | [28.6 d](/filings/0001104659-26-025308.md) | [(25.8)](/filings/0001104659-26-058703.md) | [(46.6) d](/filings/0001104659-26-091262.md) | [(46.3) d](/filings/0001104659-25-107852.md) | [(19.7) d](/filings/0001104659-26-025308.md) | [(57.9)](/filings/0001104659-26-058703.md) | [(62.1) d](/filings/0001104659-26-091262.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001558370-23-017779.md) | [0.0 d](/filings/0001558370-24-003436.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [77.7](/filings/0001558370-23-017779.md) | [79.3](/filings/0001558370-24-007641.md) | [87.3](/filings/0001558370-24-011629.md) | [97.7](/filings/0001558370-24-014648.md) | [113](/filings/0001558370-25-007418.md) | [115](/filings/0001558370-25-010803.md) | [115](/filings/0001104659-25-107852.md) | [116](/filings/0001104659-26-091262.md) | [116](/filings/0001104659-26-091262.md) | [116](/filings/0001104659-25-107852.md) | [136](/filings/0001104659-26-058703.md) | [155](/filings/0001104659-26-091262.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 154,500,966 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001104659-26-091262.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.